Mirzaten (Mirtazapine)

Mirtazapine blocks presynaptic α2‑adrenergic receptors, increasing norepinephrine release, and antagonizes serotonin 5‑HT2 and 5‑HT3 receptors while strongly inhibiting H1 histamine receptors. This dual action enhances noradrenergic and serotonergic neurotransmission, producing antidepressant and anxiolytic effects.

The dose of Mirzaten is individualized. A qualified prescriber determines the appropriate starting dose and any subsequent adjustments based on the patient’s clinical response, tolerability, and overall health status.

Data on mirtazapine use during pregnancy and lactation are limited. It is generally recommended to avoid use unless the potential benefit outweighs the risk. Pregnant or nursing patients should discuss alternatives with their healthcare provider.

To order Mirzaten, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with selective serotonin reuptake inhibitors (SSRIs), mirtazapine offers a distinct receptor profile that often results in greater sedation and appetite stimulation, which can be advantageous for patients with insomnia or weight loss. However, its side‑effect spectrum differs, and individual response varies.

Mirzaten tablets should be stored at ambient temperature, preferably below 25 °C. Keep them in the original blister pack, protect from moisture and direct sunlight, and keep out of reach of children.

Mirzaten is taken orally, usually once daily in the evening. It can be swallowed with or without food, but taking it with a light snack may reduce gastrointestinal discomfort for some patients.

Serious risks include agranulocytosis or severe neutropenia, seizures, significant hepatic injury, emergence or worsening of suicidal thoughts, and rare hypersensitivity reactions such as Stevens‑Johnson syndrome. Patients should seek immediate medical attention if any of these occur.

Mirzaten should not be used by individuals with known hypersensitivity to mirtazapine or any of its excipients, and it is contraindicated in patients currently receiving monoamine oxidase inhibitors (MAOIs) or who have taken an MAOI within the past 14 days.